Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07328607

Outcomes After Laparoscopic Versus Open Pancreaticoduodenectomy

This is a monocentric, prospective, randomized controlled trial comparing the safety and efficacy of laparoscopic pancreaticoduodenectomy (LPD) versus open pancreaticoduodenectomy (OPD). The study aims to determine the morbimortality of the laparoscopic approach compared to the gold standard open approach in adult patients with pancreatic or periampullary lesions.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Liver and GIT hospital , Minia University

Minya, Minya Governorate, 61519, Egypt

Location status: Recruiting

Location contact

Saleh K Saleh, MD

CONTACT

[email protected]

01201765401

About this study

This is a monocentric, prospective, randomized controlled trial comparing the safety and efficacy of laparoscopic pancreaticoduodenectomy (LPD) versus open pancreaticoduodenectomy (OPD). The study aims to determine the morbimortality of the laparoscopic approach compared to the gold standard open approach in adult patients with pancreatic or periampullary lesions.

This study will randomize 90 eligible patients to receive either LPD or OPD. The primary objective is to compare overall morbidity using the Clavien-Dindo Classification at 90 days postoperative. Secondary objectives include assessment of oncologic outcomes (lymph node harvest, margin status), perioperative metrics (operative time, blood loss), and postoperative recovery (length of stay, readmissions). The study utilizes a prospectively maintained database and adheres to CONSORT guidelines.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥18 years.
  • Histologically confirmed or clinically suspected lesions of: Pancreatic head adenocarcinoma, Ampullary carcinoma, Distal cholangiocarcinoma, Duodenal adenocarcinoma, Pancreatic neuroendocrine tumors, or Intraductal Papillary Mucinous Neoplasm(IPMN) .
  • Resectable disease based on preoperative imaging.
  • Eastern Cooperative Oncology Group(ECOG) performance status 0-2.
  • American Society of Anesthesiologists(ASA )classification I-III.
  • Patients able to provide informed consent.

Exclusion criteria

  • Emergency surgery.
  • Previous pancreatic surgery.
  • Concurrent major abdominal procedures .
  • ASA classification IV or higher.
  • Metastatic disease identified preoperatively.
  • Locally advanced unresectable disease.
  • Active infection or sepsis at time of surgery.
  • Severe cardiopulmonary comorbidities precluding major surgery.
  • Pregnancy.
  • Procedures requiring Total Pancreatectomy, Distal Pancreatectomy, or Enucleation .

Treatment and study plan

Open Pancreaticoduodenectomy

Procedure

Open Pancreaticoduodenectomy with lymphadenectomy and reconstruction via open technique.

laparoscopic pancreaticoduodenectomy

Procedure

Minimally invasive Whipple procedure using 6 trocars, with specimen extraction via Pfannenstiel incision.

Primary outcomes

  1. Overall Morbidity (Clavien-Dindo Classification)

    Time frame: 90 days postoperative.

    Assessment of all surgical complications graded by severity using the Clavien-Dindo Classification (Grades I-V). Major complications are defined as Grade III or higher.

Secondary outcomes

  1. Number of Lymph Nodes Retrieved

    Time frame: 14 days postoperative.

    Total count of lymph nodes harvested and examined by pathology.

  2. Resection Margin Status (R0/R1/R2)

    Time frame: 14 days postoperative.

    Pathological assessment of margins (Pancreatic neck, bile duct, retroperitoneal, etc.) classified as R0 (>1mm), R1 (≤1mm), or R2 (macroscopic).

  3. Operative Time

    Time frame: Intraoperative

    Time measured from skin incision to skin closure.

  4. Estimated Blood Loss

    Time frame: Intraoperative

    Total blood loss recorded by the anesthesiology team.

  5. Length of Hospital Stay

    Time frame: Up to 90 days.

    Total number of days from admission to discharge.

Study contacts

Contact information is provided by the study sponsor or research team.

Saleh K Saleh, MD

CONTACT

[email protected]

01201765401 ext. +2

Sponsors and collaborators

Lead sponsor

Minia University

Other

Registry information

Official study title

Open Versus Laparoscopic Pancreaticoduodenectomy: A Randomized Controlled Trial

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Jan 9, 2026
Registry last updated
Jan 21, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.